TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Being Patient report describes four leading explanations for Alzheimer’s: amyloid buildup, tau tangles, neuroinflammation and other contributing processes. The theories are not settled or mutually exclusive; research and treatments have established some links while leaving the sequence and underlying causes uncertain.
A Being Patient report explains that researchers have four leading theories for why Alzheimer’s disease damages and kills brain cells, but no single account explains the disease fully. The proposed mechanisms include amyloid plaques, tau tangles, inflammation and other processes; their relationships remain under investigation, shaping both current treatments and future research.
Alzheimer’s progressively harms neurons and the connections they use to communicate. Damage often affects the hippocampus, which is central to forming new memories, and can later affect language, judgment, behavior and coordination. The report cites the Alzheimer’s Association’s 2026 Facts and Figures estimate that 7.4 million Americans aged 65 and older are living with Alzheimer’s dementia.
The amyloid hypothesis proposes that beta-amyloid fragments accumulate outside neurons, forming plaques that may disrupt signaling and trigger further damage, including tau changes. The report says amyloid buildup can begin years before symptoms. Treatments targeting amyloid have produced mixed outcomes: it describes Leqembi (lecanemab) and Kisunla (donanemab) as FDA-approved for people in early Alzheimer’s, with trials showing modestly slower cognitive decline, not a cure. It also notes risks including brain swelling and bleeding that require monitoring.
A second account focuses on tau tangles inside neurons. Tau normally helps stabilize the cell’s internal transport structures; abnormal tau can form tangles and interfere with cell function. The report also discusses neuroinflammation and additional biological processes as potential contributors. The supplied source excerpt ends partway through its tau section, so it does not provide full detail on the fourth theory or the evidence behind it.
How the Theories Shape Treatment
Understanding the mechanisms matters because each theory points toward different ways to detect or slow disease. Amyloid is already used in diagnostic testing and targeted by approved drugs. The report says plaques can be identified through amyloid PET scans and spinal-fluid testing, and that in May 2025 the FDA cleared a blood test to aid in identifying amyloid pathology linked to Alzheimer’s.
Yet removing a disease marker does not mean the underlying condition has been stopped. The report describes the clinical benefit of newer antibodies as modest, with monitoring needed for safety risks. Other processes may contribute to neuronal injury, and therapies aimed at them remain an area of research. For readers, the distinction is important: a leading theory is a scientific explanation under study, not a complete or proven account of every person’s disease.
As an affiliate, we earn on qualifying purchases.
From Plaques to Multiple Mechanisms
In 1906, psychiatrist Alois Alzheimer described plaques and twisted fibers in the brain of Auguste Deter, a former patient who died at 55 after worsening memory loss and other symptoms. Those observations are now associated with amyloid plaques and tau tangles, two hallmarks still central to Alzheimer’s research.
For more than three decades, the amyloid hypothesis has been a dominant explanation and has guided much drug development. The report notes that Aduhelm (aducanumab), an earlier anti-amyloid drug, cleared plaques but had unconvincing evidence of clinical benefit; its maker discontinued it in 2024. The differing outcomes have kept debate alive over how amyloid relates to symptoms and whether it is a cause, a trigger or one part of a wider disease process.
““Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.””
— Bruno Imbimbo, a researcher at Chiesi Farmaceutici, as quoted by Being Patient
As an affiliate, we earn on qualifying purchases.
The Cause Remains Unsettled
Researchers have not established a single cause or a complete sequence explaining how Alzheimer’s begins and progresses. It remains uncertain how the proposed mechanisms interact, which changes are drivers rather than consequences, and why disease progression differs among people. The source excerpt gives only partial coverage of the tau discussion and does not name or explain its fourth theory in full, so further specifics cannot be reliably reported from the material provided.
The treatment evidence also has limits. The report characterizes the cognitive slowing seen with lecanemab and donanemab as modest and notes risks that call for monitoring. These findings do not establish that amyloid alone explains Alzheimer’s or that removing plaques prevents or reverses the disease.
As an affiliate, we earn on qualifying purchases.
Research Must Test Each Pathway
Research will continue testing how amyloid, tau, inflammation and other biological processes contribute to neuronal damage, and whether combinations of treatments can improve outcomes. The report provides no specific upcoming study result or regulatory decision. For now, approved early-stage amyloid treatments and available biomarker tests are part of a changing research and care landscape, while the underlying cause remains an open scientific question.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the four leading theories about Alzheimer’s?
The report covers amyloid buildup and tau tangles, and identifies neuroinflammation and other biological processes as possible contributors. The supplied excerpt does not fully detail a distinct fourth theory, so it does not support a more specific four-item list.
Is amyloid proven to be the cause of Alzheimer’s?
No single cause is established. Amyloid is a major research theory and a treatment target, but the report describes ongoing debate over its role and says other processes may also contribute.
Do amyloid-targeting drugs cure Alzheimer’s?
No. The report says trials of lecanemab and donanemab found modestly slower cognitive decline in early Alzheimer’s, not a cure. It also notes risks such as brain swelling and bleeding that require regular monitoring.
The report says amyloid plaques can be detected using PET scans and spinal-fluid tests. It also reports that the FDA cleared a blood test in May 2025 to aid in identifying amyloid pathology linked to Alzheimer’s.
Source: rss
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
